Literature DB >> 31729568

Relationships among body composition, muscle strength, and sarcopenia in esophageal squamous cell carcinoma patients.

Kotaro Sugawara1, Hiroharu Yamashita2, Yasuhiro Okumura2, Koichi Yagi2, Shuntaro Yoshimura2, Koichiro Kawasaki2, Asami Tanabe2, Susumu Aikou2,3, Yasuyuki Seto2.   

Abstract

PURPOSE: Relationships among body composition indices assessed by various modalities remain to be addressed in patients with esophageal squamous cell carcinoma (ESCC), in whom being underweight is more strikingly prevalent than in those with other malignancies. We investigated the relationships of body composition parameters with the sarcopenia prevalence of ESCC patients.
METHODS: In this prospective study, we analyzed preoperative data obtained from 75 ESCC patients undergoing esophagectomy. Body composition data included body mass index (BMI), skeletal muscle index (SMI) assessed by computed tomography, and parameters calculated by bioelectrical impedance analysis (skeletal muscle mass (SMM), body fat mass). Muscle strength was evaluated by handgrip strength (HGS). Sarcopenia was defined as having both low SMI and low HGS.
RESULTS: The median BMI value was 22.5 (range 15.2-28.7) in our ESCC cohort. BMI correlated significantly with fat mass (r = 0.84, P < 0.001), SMM (r = 0.57, P < 0.001) and SMI (r = 0.49, P < 0.001). Similarly, SMI showed a significant correlation with SMM (r = 0.45, P < 0.001). Meanwhile, HGS was highly correlated with SMM (r = 0.67, P < 0.001), while showing significant but weak associations with both BMI and SMI (r = 0.33, 0.34, respectively, P < 0.001). Notably, sarcopenia prevalence differed markedly according to BMI category; 28.6%, 12.2%, and 0% in the low (< 20), medium (20-25), and high (> 25) BMI groups, respectively.
CONCLUSIONS: BMI reflects comprehensive information on body composition in ESCC patients, although its correlation with muscle mass and muscle strength was moderate. Decreased BMI might serve as an indicator for sarcopenia in this population, in which the presence of sarcopenic obesity is rare.

Entities:  

Keywords:  Body mass index; Esophageal squamous cell carcinoma; Muscle strength; Sarcopenia; Skeletal muscle mass

Mesh:

Year:  2019        PMID: 31729568     DOI: 10.1007/s00520-019-05110-7

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  4 in total

1.  Impact of losing adipose tissue on outcomes from PD-1/PD-L1 inhibitor monotherapy in non-small cell lung cancer.

Authors:  Naoya Nishioka; Tateaki Naito; Taichi Miyawaki; Michitoshi Yabe; Kosei Doshita; Hiroaki Kodama; Eriko Miyawaki; Yuko Iida; Nobuaki Mamesaya; Haruki Kobayashi; Shota Omori; Ryo Ko; Kazushige Wakuda; Akira Ono; Hirotsugu Kenmotsu; Haruyasu Murakami; Koichi Takayama; Toshiaki Takahashi
Journal:  Thorac Cancer       Date:  2022-04-14       Impact factor: 3.223

2.  Prognostic Impact of Sarcopenic Obesity after Neoadjuvant Chemotherapy Followed by Surgery in Elderly Patients with Esophageal Squamous Cell Carcinoma.

Authors:  Sachiyo Onishi; Masahiro Tajika; Tsutomu Tanaka; Keisaku Yamada; Tetsuya Abe; Eiji Higaki; Takahiro Hosoi; Yoshitaka Inaba; Kei Muro; Masahito Shimizu; Yasumasa Niwa
Journal:  J Clin Med       Date:  2020-09-15       Impact factor: 4.241

3.  A Nutrition-Related Factor-Based Risk Stratification for Exploring the Clinical Benefits in the Treatment of Patients With Locally Advanced Esophageal Squamous Cell Carcinoma Receiving Definitive Chemoradiotherapy: A Retrospective Cohort Study.

Authors:  Yilin Yu; Haishan Wu; Jianjian Qiu; Dongmei Ke; Yahua Wu; Mingqiang Lin; Tianxiu Liu; Qunhao Zheng; Hongying Zheng; Jun Yang; Zhiping Wang; Hui Li; Lingyun Liu; Qiwei Yao; Jiancheng Li; Wenfang Cheng; Xiaohui Chen
Journal:  Front Nutr       Date:  2022-08-04

4.  LOX and Its Methylation Impact Prognosis of Diseases and Correlate with TAM Infiltration in ESCA.

Authors:  Chuanqiang Wu; Bin Jiang; Zixiang Wu; Lingjun Dong; Keyi Sun; Ming Wu
Journal:  J Oncol       Date:  2022-08-31       Impact factor: 4.501

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.